Boundless Bio (BOLD) vs Tenax Therapeutics (TENX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Boundless Bio (BOLD) has outperformed Tenax Therapeutics (TENX) over the past year, gaining 105.3% versus a loss of 84.7%. Tenax Therapeutics is the larger company by market cap ($56.9 million vs $54.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BOLD | TENX |
|---|---|---|
| Share price | $2.32 | $1.25 |
| Market cap | $54.78M | $56.92M |
| 1-day change | -2.52% | -10.07% |
| YTD return | +93.33% | -89.75% |
| 1-year return | +105.31% | -84.66% |
| 5-year return | — | -99.94% |
| EPS (TTM) | $-2.46 | $-1.39 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $0 |
| Net income (latest FY) | $-58.20M | $-52.60M |
| 52-week high | $3.16 | $19.40 |
| 52-week low | $0.961 | $1.24 |
| Distance from 52-week high | -26.68% | -93.56% |
| Analyst consensus | none | none |
| Avg. price target upside | +72.41% | +904.80% |
| Average volume | 131.34K | 3.15M |
| Shares outstanding | 23.61M | 45.54M |
| Employees | 28 | 14 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BOLD has outperformed TENX by 190.0 percentage points over the past year.
About Boundless Bio
BOLD stock →Boundless Bio, Inc., a clinical-stage oncology company, develops interrogating extrachromosomal DNA (ecDNA) directed therapies for treating patients with oncogene amplified cancers. Its lead product candidate is BBI-940, an ecDNA-directed therapeutic candidate (ecDTx) that is in Phase 1/2 clinical trial in patients with estrogen receptor positive and human epidermal growth factor receptor 2 negative breast cancer, as well as patients with triple-negative breast cancer luminal androgen receptor subtype.
Health Care · Biotechnology: Pharmaceutical Preparations · 28 employees
About Tenax Therapeutics
TENX stock →Tenax Therapeutics, Inc., a development-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.
Health Care · Biotechnology: Pharmaceutical Preparations · 14 employees
BOLD vs TENX FAQ
Which is bigger, Boundless Bio or Tenax Therapeutics?
Tenax Therapeutics (TENX) is larger, with a market capitalization of $56.92M compared with $54.78M for Boundless Bio (BOLD).
Which stock has performed better over the past year, BOLD or TENX?
BOLD returned +105.31% over the past 12 months, compared with -84.66% for TENX (price return, excluding dividends). Past performance does not predict future results.
Are Boundless Bio and Tenax Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.